5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Controlled release of metronidazole benzoate from poly ε-caprolactone electrospun nanofibers for periodontal diseases

      , , ,
      European Journal of Pharmaceutics and Biopharmaceutics
      Elsevier BV

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Poly epsilon-caprolactone (PCL) nanofibers containing metronidazole benzoate (MET) were successfully electrospun and evaluated for periodontal diseases. Solutions of 10.5% w/v PCL and 5-15%w/w MET in mixtures of dichloromethane (DCM)/N,N-dimethylformamide (DMF) with ratios of 90:10, 80:20 and 70:30 v/v were prepared, and the nanofibers were produced by electrospinning technique. Scanning electron microscopy (SEM) was used to investigate the morphology and average diameter of the electrospun nanofibers. DSC results indicated a molecular dispersion of MET in the PCL nanofibers and showed a decrease in crystallinity of PCL nanofibers by adding MET. Results showed that an increase in the DCM:DMF ratio led to a decrease in the solution conductivity and an increase in the solution viscosity as well as in the nanofibers diameter. Also increasing metronidazole benzoate concentration caused an increase in the solution conductivity and a decrease in the solution viscosity as well as in the nanofibers diameter. In vitro drug release studies in phosphate buffer solution (pH 7.4) showed that the drug release rate was affected by the solvents ratio and the drug concentration. Moreover, the burst release was low, and sustained drug release was prolonged to at least 19 days. Copyright 2010 Elsevier B.V. All rights reserved.

          Related collections

          Author and article information

          Journal
          European Journal of Pharmaceutics and Biopharmaceutics
          European Journal of Pharmaceutics and Biopharmaceutics
          Elsevier BV
          09396411
          June 2010
          June 2010
          : 75
          : 2
          : 179-185
          Article
          10.1016/j.ejpb.2010.02.002
          20144711
          320dab7a-f284-4d56-bd90-d795f7461859
          © 2010

          https://www.elsevier.com/tdm/userlicense/1.0/

          History

          Comments

          Comment on this article